Raptiva Off and Running

Article

San Francisco - A study on Raptiva (efalizumab) shows patients with moderate-to-severe plaque psoriasis who received 12 weeks of treatment experienced a significant reduction in signs and symptoms, and patients who continued treatment to 24 weeks continued to benefit.

Related Videos
Related Content

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.